FirstWord

Former Galapagos CEO Paul Stoffels' new company, Armed Cell Therapeutics, is buying preclinical armored CAR-T assets from the rebranded drugmaker, now known as Lakefront Biotherapeutics.

The AI-focused drug discovery company sold 9.4 million shares at $16 apiece, the midpoint of its proposed range.

insitro will use its Virtual Human AI platform to identify novel targets for metabolic dysfunction-associated steatohepatitis and cardiomyopathies.

Proceeds will be used to move the melanocortin-2 receptor antagonist OMS1620 into the clinic for congenital adrenal hyperplasia and ACTH-dependent Cushing's syndrome.

VQW-765 fell short on the primary endpoint in Study 3201 for social anxiety disorder, failing to replicate its earlier mid-stage success in the same indication.

Joint initiative demonstrates how risk-based, value-based partnerships can convert a well-established clinical practice into meaningful, scaled savings across a shared patient populationNASHVILLE, Ten...

FirstWord will be speaking with a leading retinal specialist about detailed Phase IIb/III BRUNELLO data for Merck's remigromig to treat DME, and what they say about the prospects for it and other Wnt-directed therapies in retinal diseases.

World Vaccine Congress Europe 2026 panel entitled, From Non-Inferiority to Impact: Accelerating Adoption of Needle-Free Vaccine Delivery, will explore how new, needle-free delivery technologies may im...

Posters to highlight assessments of treatment with immediate-use seizure medicationSAN DIEGO, Oct. 15, 2026 /PRNewswire/ -- Neurelis, Inc., a neuroscience company focused on the development and commer...

Clinical and scientific data presentations in support of Gvoke® (glucagon) injection, Recorlev® (levoketoconazole), and the investigational XP-8121 program underscore Xeris's leadership in endocrinolo...